When was RS Research founded?

RS Research was founded in 2015.

Where is RS Research located?

RS Research is headquartered in Pendik, Turkey.

How many employees does RS Research have?

As of Aug 31, 2026, the latest employee count at RS Research is 30.

Is RS Research a funded company?

RS Research is a funded company, having raised a total of $14.3M across 6 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round.

When was the latest funding round of RS Research?

RS Research's latest funding was a $***** Grant (prize money) round on Mar 19, 2024, with participation from 1 investor.

Where does RS Research rank among its competitors?

RS Research ranks 373rd amongst 2752 active competitors, of which 919 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of RS Research?

RS Research's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

RS Research - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of smart nanomedicines and targeted oncology therapies using polymer-drug conjugate platforms. This biotechnology company focuses on disrupting the efficacy-toxicity trade-off in cancer treatment through the creation of targeted chemotherapy and theranostics. By utilizing advanced delivery platforms, the company aims to improve the therapeutic index across a spectrum of payloads to address challenges in oncology. PF = Yes

Website: rsresearch.net
Social
Email ID: *****@rsresearch.net
Phone Number: +90 **********

Key Metrics

Founded Year

2015

Location

Pendik, Turkey

Stage

Series A

Total Funding

$14.3M in 6 rounds

Latest Funding Round

Grant (prize money), Mar 19, 2024, $*****

Investors

Gen & 4 more

Ranked

373^rd among 2752 active competitors

Employee Count

30 as on Aug 31, 2026

Similar Companies

Liquidia & 379 more

View RS Research's full profile

RS Research has raised a total funding of $14.3M over 6 rounds. Its latest funding round was a Grant (prize money) round on Mar 19, 2024 for $*****. 1 investor participated in its latest round. RS Research has 5 institutional investors.

Here is the list of recent funding rounds of RS Research:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 19, 2024	8683716	Grant (prize money)	5329511	1152604	7997021	1723945
Dec 15, 2021	9974803	Series A	1768599	8428817	3789686	Istanbul Portfolio & 2 more
Jan 07, 2018	6387584	Seed	2258590	7854570	7419501	ACT

Access funding benchmarks and valuations. Sign up today!

View details of RS Research's funding rounds and investors

The founders of RS Research are Rana Sanyal and Sena Nomak.

Here are the details of RS Research's key team members:

Rana Sanyal: Co-Founder & CSO of RS Research and founder of 1 other company. They serve on the board of 1 company.
Contact Info: 1 email address
Sena Nomak: Co-Founder & COO of RS Research. They serve on the board of 1 company.
Contact Info: 1 email address

RS Research's Board of Directors

RS Research's board has 3 active members. Rana Sanyal and Sena Nomak are part of team and Gülşah Nomak is independent board member.

Here is the list of RS Research's board of directors:

Name	Type	Representing	Status	Duration
Rana Sanyal	Team	-	Current	-
Sena Nomak	Team	-	Current	-
Gülşah Nomak	Independent board member	-	Current	-

View details of RS Research's Founder profiles and Board Members

RS Research's employee count trend

RS Research has 30 employees as of Aug 26. Here is RS Research's employee count trend over the years:

Uncover RS Research's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RS Research include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of RS Research, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
10th	Elicio 2012, Cambridge (United States), Public	Developer of vaccines for treating cancer	$47.4M	Dreavent, Efung Capital & 5 others	71/100
373rd	RS Research 2015, Pendik (Turkey), Series A	Developer of smart nanomedicines and targeted oncology therapies using polymer-drug conjugate platforms	$14.3M	Europa, ACT & 3 others	53/100